NAMSW (STOCKS)
NewAmsterdam Pharma Company N.V. Warrant
—
Change: —
Prev close: —
Company Information
- Exchange
- XNAS
- Sector
- —
- Industry
- —
- CEO
- —
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- —
- Employees
- 77
- P/E (TTM)
- —
- P/B (TTM)
- —
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $22.50M |
| Benefits Costs and Expenses | $226.32M |
| Costs And Expenses | $226.32M |
| Operating Expenses | $248.19M |
| Selling, General, and Administrative Expenses | $106.35M |
| Depreciation and Amortization | $478.00K |
| Research and Development | $141.83M |
| Operating Income/Loss | -$225.68M |
| Income/Loss From Continuing Operations After Tax | -$203.82M |
| Income/Loss From Continuing Operations Before Tax | -$203.82M |
| Net Income/Loss | -$203.82M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$203.82M |
| Net Income/Loss Available To Common Stockholders, Basic | -$203.82M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.72 |
| Diluted Earnings Per Share | -$1.72 |
| Basic Average Shares | 118,424,231 |
| Diluted Average Shares | 118,424,231 |
| Assets | $769.28M |
| Current Assets | $675.70M |
| Noncurrent Assets | $93.58M |
| Fixed Assets | $383.00K |
| Other Non-current Assets | $93.20M |
| Liabilities | $85.85M |
| Current Liabilities | $85.79M |
| Accounts Payable | $8.97M |
| Other Current Liabilities | $76.82M |
| Noncurrent Liabilities | $66.00K |
| Equity | $683.43M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $683.43M |
| Liabilities And Equity | $769.28M |
| Net Cash Flow From Operating Activities | -$147.78M |
| Net Cash Flow From Operating Activities, Continuing | -$147.78M |
| Net Cash Flow From Investing Activities | -$174.92M |
| Net Cash Flow From Investing Activities, Continuing | -$174.92M |
| Net Cash Flow From Financing Activities | $29.52M |
| Net Cash Flow From Financing Activities, Continuing | $29.52M |
| Net Cash Flow | -$293.18M |
| Net Cash Flow, Continuing | -$293.18M |
| Comprehensive Income/Loss | -$203.49M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$203.49M |
| Other Comprehensive Income/Loss | $326.00K |